BRIAN GAYNOR: The rise and rise of Fisher & Paykel Healthcare

BRIAN GAYNOR: The rise and rise of Fisher & Paykel Healthcare
Brian Gaynor
Fisher & Paykel Healthcare has been a fantastic investment in recent years, particularly during the covid-19 pandemic.At the end of June, the medical supplies company had a share market value of $20.5 billion, making it the first $20 billion NZX company. Its performance during the covid-19 crisis has been amazing with its total market value surging $7.1 billion between Jan. 31 and June 30. This value accretion was greater than the total value of all but four other NZX listed stocks: A2 Milk, Meridian Energy, Auckland International...

More Opinion

Benchmark-beaters: how ESG gives indexers active power
Opinion

David Chaplin: Benchmark-beaters: how ESG gives indexers active power

The ESG push among institutional investors is changing the mix.

David Chaplin 03 Jul 2024
Has ArborGen finally crossed the Rubicon?
Opinion

Paul McBeth: Has ArborGen finally crossed the Rubicon?

Long-suffering shareholders might be dubious about the emerging green shoots.

Paul McBeth 02 Jul 2024
Our nation of tinkerers
Opinion

Simon Robertson: Our nation of tinkerers

From wine to Wētā, New Zealanders are always excelling at something.  

Simon Robertson 29 Jun 2024
How to protect your business's brand
Opinion

Georgina Toomey: How to protect your business's brand

Monitor anyone using your trademarks to protect it. 

Georgina Toomey 27 Jun 2024